346 related articles for article (PubMed ID: 24844220)
1. Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML
Int J Gynecol Cancer; 2014 Jun; 24(5):865-73. PubMed ID: 24844220
[TBL] [Abstract][Full Text] [Related]
2. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
King MT; Stockler MR; O'Connell RL; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Sehouli J; Feeney A; Berton-Rigaud D; Costa DSJ; Friedlander ML;
Qual Life Res; 2018 Jan; 27(1):59-74. PubMed ID: 29248998
[TBL] [Abstract][Full Text] [Related]
3. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT;
Int J Gynecol Cancer; 2014 Jun; 24(5):857-64. PubMed ID: 24844219
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
5. Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis.
Donovan HS; Hagan TL; Campbell GB; Boisen MM; Rosenblum LM; Edwards RP; Bovbjerg DH; Horn CC
Support Care Cancer; 2016 Jun; 24(6):2635-42. PubMed ID: 26746209
[TBL] [Abstract][Full Text] [Related]
6. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky MC; Diamante K; Stockler MR; Friedlander ML;
Int J Gynecol Cancer; 2022 Jun; 32(6):761-768. PubMed ID: 35086926
[TBL] [Abstract][Full Text] [Related]
7. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
8. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
Piccirillo MC; Scambia G; Bologna A; Signoriello S; Vergote I; Baumann K; Lorusso D; Murgia V; Sorio R; Ferrandina G; Sacco C; Cormio G; Breda E; Cinieri S; Natale D; Mangili G; Pisano C; Cecere SC; Di Napoli M; Salutari V; Raspagliesi F; Arenare L; Bergamini A; Bryce J; Daniele G; Gallo C; Pignata S; Perrone F
Ann Oncol; 2018 May; 29(5):1189-1194. PubMed ID: 29462248
[TBL] [Abstract][Full Text] [Related]
9. Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Campbell R; Costa DSJ; Stockler MR; Lee YC; Ledermann JA; Berton D; Sehouli J; Roncolato FT; Connell RO; Okamoto A; Bryce J; Oza AM; Avall-Lundqvist E; Berek JS; Lanceley A; Joly F; Hilpert F; Feeney A; Kaminsky MC; Diamante K; Friedlander ML; King MT;
Gynecol Oncol; 2022 Aug; 166(2):254-262. PubMed ID: 35718565
[TBL] [Abstract][Full Text] [Related]
10. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer.
Greimel E; Bottomley A; Cull A; Waldenstrom AC; Arraras J; Chauvenet L; Holzner B; Kuljanic K; Lebrec J; D'haese S;
Eur J Cancer; 2003 Jul; 39(10):1402-8. PubMed ID: 12826043
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in ovarian cancer patients receiving chemotherapy.
Lakusta CM; Atkinson MJ; Robinson JW; Nation J; Taenzer PA; Campo MG
Gynecol Oncol; 2001 Jun; 81(3):490-5. PubMed ID: 11371144
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.
Friedlander M; Rau J; Lee CK; Meier W; Lesoin A; Kim JW; Poveda A; Buck M; Scambia G; Shimada M; Hilpert F; King MT; Debruyne P; Bologna A; Malander S; Monk BJ; Petru E; Calvert P; Herzog TJ; Barrett C; du Bois A
Ann Oncol; 2018 Mar; 29(3):737-743. PubMed ID: 29267856
[TBL] [Abstract][Full Text] [Related]
13. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.
Doyle C; Crump M; Pintilie M; Oza AM
J Clin Oncol; 2001 Mar; 19(5):1266-74. PubMed ID: 11230467
[TBL] [Abstract][Full Text] [Related]
14. Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review.
Moss CL; Guerrero-Urbano T; White I; Taylor B; Kristeleit R; Montes A; Fox L; Beyer K; Sztankay M; Ratti MM; Sisca ES; Derevianko A; MacLennan S; Wood N; Wintner LM; Van Hemelrijck M
Future Oncol; 2023 Mar; 19(9):663-678. PubMed ID: 37128990
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry.
Ezendam NP; Pijlman B; Bhugwandass C; Pruijt JF; Mols F; Vos MC; Pijnenborg JM; van de Poll-Franse LV
Gynecol Oncol; 2014 Dec; 135(3):510-7. PubMed ID: 25281491
[TBL] [Abstract][Full Text] [Related]
16. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites.
Easson AM; Bezjak A; Ross S; Wright JG
Ann Surg Oncol; 2007 Aug; 14(8):2348-57. PubMed ID: 17505860
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; Pujade-Lauraine E; du Bois A; ;
Support Care Cancer; 2011 Sep; 19(9):1421-7. PubMed ID: 20694564
[TBL] [Abstract][Full Text] [Related]
18. Quality of Life in Platinum-Sensitive Recurrent Ovarian Cancer: Chemotherapy Versus Surgery Plus Chemotherapy.
Plotti F; Scaletta G; Aloisi A; Luvero D; Capriglione S; Miranda A; Montera R; De Cicco Nardone C; Terranova C; Angioli R
Ann Surg Oncol; 2015 Jul; 22(7):2387-94. PubMed ID: 25582738
[TBL] [Abstract][Full Text] [Related]
19. The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors.
Knobel H; Loge JH; Brenne E; Fayers P; Hjermstad MJ; Kaasa S
Palliat Med; 2003 Dec; 17(8):664-72. PubMed ID: 14694917
[TBL] [Abstract][Full Text] [Related]
20. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Roncolato FT; Joly F; O'Connell R; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Heitz F; Feeney A; Berton-Rigaud D; Stockler MR; King M; Friedlander M;
Oncologist; 2017 Sep; 22(9):1117-1124. PubMed ID: 28596446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
